KR102551971B1 - 과인산화된 타우에 특이적인 항체 및 이의 사용 방법 - Google Patents
과인산화된 타우에 특이적인 항체 및 이의 사용 방법 Download PDFInfo
- Publication number
- KR102551971B1 KR102551971B1 KR1020197001135A KR20197001135A KR102551971B1 KR 102551971 B1 KR102551971 B1 KR 102551971B1 KR 1020197001135 A KR1020197001135 A KR 1020197001135A KR 20197001135 A KR20197001135 A KR 20197001135A KR 102551971 B1 KR102551971 B1 KR 102551971B1
- Authority
- KR
- South Korea
- Prior art keywords
- seq
- amino acid
- acid sequence
- antibody
- tau
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Microbiology (AREA)
- Psychology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Cardiology (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201600416 | 2016-07-12 | ||
| DKPA201600416 | 2016-07-12 | ||
| DKPA201700008 | 2017-01-04 | ||
| DKPA201700005 | 2017-01-04 | ||
| DKPA201700005 | 2017-01-04 | ||
| DKPA201700008 | 2017-01-04 | ||
| DKPA201700179 | 2017-03-14 | ||
| DKPA201700179 | 2017-03-14 | ||
| PCT/EP2017/067067 WO2018011073A1 (en) | 2016-07-12 | 2017-07-07 | Antibodies specific for hyperphosphorylated tau and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20190028436A KR20190028436A (ko) | 2019-03-18 |
| KR102551971B1 true KR102551971B1 (ko) | 2023-07-07 |
Family
ID=60941665
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020197001135A Active KR102551971B1 (ko) | 2016-07-12 | 2017-07-07 | 과인산화된 타우에 특이적인 항체 및 이의 사용 방법 |
Country Status (41)
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107412788B (zh) | 2012-12-21 | 2021-06-18 | 国立研究开发法人量子科学技术研究开发机构 | 用于对脑内所蓄积的Tau蛋白质进行成像的新的化合物 |
| JP6793134B2 (ja) | 2015-06-05 | 2020-12-02 | ジェネンテック， インコーポレイテッド | 抗ｔａｕ抗体及び使用方法 |
| JO3711B1 (ar) | 2015-07-13 | 2021-01-31 | H Lundbeck As | أجسام مضادة محددة لبروتين تاو وطرق استعمالها |
| HUE053679T2 (hu) | 2016-07-12 | 2021-07-28 | H Lundbeck As | Hiperfoszforilezett TAU-ra specifikus antitestek és eljárások ezek alkalmazására |
| WO2018106776A2 (en) | 2016-12-07 | 2018-06-14 | Genentech, Inc. | Anti-tau antibodies and methods of use |
| MY198942A (en) | 2016-12-07 | 2023-10-03 | Genentech Inc | Anti-tau antibodies and methods of use |
| US10995137B2 (en) | 2017-01-04 | 2021-05-04 | H. Lundbeck A/S | Antibodies specific for hyperphosphorlated tau for the treatment of ocular diseases |
| WO2018152359A1 (en) | 2017-02-17 | 2018-08-23 | Denali Therapeutics Inc. | Anti-tau antibodies and methods of use thereof |
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| TWI853617B (zh) | 2017-10-16 | 2024-08-21 | 日商衛材R&D企管股份有限公司 | 抗tau抗體及其用途 |
| WO2019149798A1 (en) * | 2018-02-01 | 2019-08-08 | Janssen Vaccines & Prevention B.V. | Binding molecules that specifically bind to tau |
| KR20200130350A (ko) | 2018-03-05 | 2020-11-18 | 얀센 파마슈티카 엔.브이. | 항-phf-타우 항체 및 이의 용도 |
| MX2020011959A (es) | 2018-05-09 | 2021-02-17 | Aprinoia Therapeutics Ltd | Compuestos de heteroarilo y usos de los mismos. |
| WO2020087031A1 (en) | 2018-10-26 | 2020-04-30 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| US12365724B2 (en) | 2018-12-10 | 2025-07-22 | New York University | Antibodies binding to phospho-tau comprising phosphorylated Ser396 and Ser404 and methods of detecting thereof |
| CA3127113A1 (en) | 2019-01-30 | 2020-08-06 | Dongxu Sun | Anti-gal3 antibodies and uses thereof |
| JP2022527087A (ja) | 2019-03-28 | 2022-05-30 | ハー・ルンドベック・アクチエゼルスカベット | タウオパチーを診断するためのｐＳ３９６アッセイの使用 |
| CN114641490B (zh) | 2019-08-06 | 2023-06-06 | 新旭生技股份有限公司 | 结合至病理性tau种类的抗体及其用途 |
| CN114728071B (zh) | 2019-11-13 | 2024-12-06 | 新旭生技股份有限公司 | 用于降解tau蛋白聚集体的化合物及其用途 |
| JP2023528797A (ja) | 2020-05-26 | 2023-07-06 | トゥルーバインディング，インコーポレイテッド | ガレクチン－３を遮断することにより炎症性疾患を処置する方法 |
| CN117716034A (zh) | 2021-07-27 | 2024-03-15 | 斯坦德治疗有限公司 | 肽标签和编码该肽标签的核酸 |
| KR20240049361A (ko) * | 2021-08-25 | 2024-04-16 | 아이바이오, 인크. | 항-cd25 항체 |
| WO2025090817A1 (en) * | 2023-10-24 | 2025-05-01 | Janssen Pharmaceuticals, Inc. | Tau active functional assays |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| EP0098110B1 (en) | 1982-06-24 | 1989-10-18 | NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD | Long-acting composition |
| US4681581A (en) | 1983-12-05 | 1987-07-21 | Coates Fredrica V | Adjustable size diaper and folding method therefor |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
| US4735210A (en) | 1985-07-05 | 1988-04-05 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US5101827A (en) | 1985-07-05 | 1992-04-07 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4861581A (en) | 1986-12-05 | 1989-08-29 | Cancer Biologics, Inc. | Detection of necrotic malignant tissue and associated therapy |
| US5750172A (en) | 1987-06-23 | 1998-05-12 | Pharming B.V. | Transgenic non human mammal milk |
| US5648471A (en) | 1987-12-03 | 1997-07-15 | Centocor, Inc. | One vial method for labeling antibodies with Technetium-99m |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| JP3070763B2 (ja) | 1989-08-09 | 2000-07-31 | ロメッド インコーポレイティド | テクネチウムまたはレニウムでの抗体または他のタンパク質の直接放射能標識 |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| AU8507191A (en) | 1990-08-29 | 1992-03-30 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| AU2235992A (en) | 1991-06-14 | 1993-01-12 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
| DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
| CA2113113A1 (en) | 1991-07-08 | 1993-01-21 | Simon W. Kantor | Thermotropic liquid crystal segmented block copolymer |
| DE69233723T2 (de) | 1991-12-06 | 2009-02-05 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Verwendung von Proteinkinasen zur Diagnose und Behandlung der Alzheimer Krankheit |
| EP0746609A4 (en) | 1991-12-17 | 1997-12-17 | Genpharm Int | NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES |
| DK0804070T3 (da) | 1993-03-09 | 2000-08-07 | Genzyme Corp | Fremgangsmåde til isolering af proteiner fra mælk |
| CA2161351C (en) | 1993-04-26 | 2010-12-21 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US6077835A (en) | 1994-03-23 | 2000-06-20 | Case Western Reserve University | Delivery of compacted nucleic acid to cells |
| KR970029803A (ko) | 1995-11-03 | 1997-06-26 | 김광호 | 반도체 메모리장치의 프리차지 회로 |
| US6355271B1 (en) | 1999-02-03 | 2002-03-12 | Biosante Pharmaceuticals, Inc. | Therapeutic calcium phosphate particles and methods of manufacture and use |
| US6281005B1 (en) | 1999-05-14 | 2001-08-28 | Copernicus Therapeutics, Inc. | Automated nucleic acid compaction device |
| IL147765A0 (en) | 1999-07-29 | 2002-08-14 | Medarex Inc | HUMAN MONOCLONAL ANTIBODIES TO HER2/neu |
| ES2282133T3 (es) | 1999-08-24 | 2007-10-16 | Medarex, Inc. | Anticuerpos frente a la ctla-4 humano y sus usos. |
| US20030162230A1 (en) | 2000-09-27 | 2003-08-28 | Reagan Kevin J. | Method for quantifying phosphokinase activity on proteins |
| MXPA03004793A (es) | 2000-11-30 | 2004-12-03 | Medarex Inc | Roedores transgenicos transcromosomales para elaborar anticuerpos humnanos. |
| AT500379B8 (de) * | 2001-02-02 | 2009-08-15 | Axon Neuroscience | Tau-proteine |
| CN1671416B (zh) | 2001-07-12 | 2013-01-02 | 杰斐逊·富特 | 超人源化抗体 |
| US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
| JP2009506302A (ja) | 2005-08-04 | 2009-02-12 | イェシバ・ユニバーシティ | Ａｂｌによるタウのリン酸化 |
| EP1973576B1 (en) | 2005-11-28 | 2019-05-15 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| US9693539B2 (en) | 2007-08-10 | 2017-07-04 | E. R. Squibb & Sons, L.L.C. | HCO32 and HCO27 and related examples |
| EP2527369A3 (en) * | 2007-09-13 | 2012-12-19 | University Of Zurich Prorektorat Forschung | Monoclonal amyloid beta (abeta)-specific antibody and uses thereof |
| CA2765099A1 (en) | 2009-06-10 | 2010-12-16 | New York University | Phosphorylated tau peptide for use in the treatment of tauopathy |
| US8609097B2 (en) | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
| EP2625198B1 (en) | 2010-10-07 | 2015-07-22 | AC Immune S.A. | Antibodies recognising phospho-tau |
| US8940272B2 (en) * | 2010-10-11 | 2015-01-27 | University Of Zurich | Human anti-tau antibodies |
| US9506051B2 (en) * | 2011-05-20 | 2016-11-29 | Oligomerix, Inc. | Tau protease compositions and methods of use |
| CN108034005B (zh) * | 2011-10-07 | 2021-06-25 | Ac免疫有限公司 | 识别Tau的磷酸化特异抗体 |
| WO2013151762A1 (en) | 2012-04-05 | 2013-10-10 | Ac Immune S.A. | Humanized tau antibody |
| MX359555B (es) | 2012-07-03 | 2018-10-02 | Univ Washington | Anticuerpos para tau. |
| EP3685854A1 (en) | 2012-08-16 | 2020-07-29 | Ipierian, Inc. | Methods of treating a tauopathy |
| CU24446B1 (es) | 2013-03-13 | 2019-10-04 | Prothena Biosciences Ltd | Un anticuerpo monoclonal humanizado que se une a tau |
| WO2014170549A1 (en) | 2013-04-16 | 2014-10-23 | Glykos Finland Oy | A method for generating induced pluripotent stem cells |
| GB201312226D0 (en) * | 2013-07-08 | 2013-08-21 | Adx Neurosciences | Improved antibodies |
| EA033260B1 (ru) | 2014-01-23 | 2019-09-30 | Асахи Касеи Кабусики Кайся | Блок-сополимерная композиция и клеевая композиция |
| US10132818B2 (en) | 2014-07-08 | 2018-11-20 | New York University | Tau imaging ligands and their uses in the diagnosis and treatment of tauopathy |
| JO3711B1 (ar) | 2015-07-13 | 2021-01-31 | H Lundbeck As | أجسام مضادة محددة لبروتين تاو وطرق استعمالها |
| HUE053679T2 (hu) | 2016-07-12 | 2021-07-28 | H Lundbeck As | Hiperfoszforilezett TAU-ra specifikus antitestek és eljárások ezek alkalmazására |
| US10364286B2 (en) | 2016-12-22 | 2019-07-30 | H. Lundbeck A/S | Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation |
| US10995137B2 (en) | 2017-01-04 | 2021-05-04 | H. Lundbeck A/S | Antibodies specific for hyperphosphorlated tau for the treatment of ocular diseases |
| US10934438B2 (en) | 2017-04-27 | 2021-03-02 | Axalta Coating Systems Ip Co., Llc | Coatings and methods for using and producing the same |
-
2017
- 2017-07-07 HU HUE17739940A patent/HUE053679T2/hu unknown
- 2017-07-07 ES ES17739940T patent/ES2862427T3/es active Active
- 2017-07-07 NZ NZ748983A patent/NZ748983A/en unknown
- 2017-07-07 EP EP20209554.3A patent/EP3878864A1/en active Pending
- 2017-07-07 GE GEAP201714957A patent/GEP20217222B/en unknown
- 2017-07-07 HR HRP20210522TT patent/HRP20210522T1/hr unknown
- 2017-07-07 TN TNP/2018/000419A patent/TN2018000419A1/en unknown
- 2017-07-07 JO JOP/2018/0117A patent/JOP20180117B1/ar active
- 2017-07-07 MA MA056165A patent/MA56165A/fr unknown
- 2017-07-07 DK DK17739940.9T patent/DK3484916T3/da active
- 2017-07-07 JP JP2018566490A patent/JP7029415B2/ja active Active
- 2017-07-07 MA MA45655A patent/MA45655B1/fr unknown
- 2017-07-07 KR KR1020197001135A patent/KR102551971B1/ko active Active
- 2017-07-07 EP EP17739940.9A patent/EP3484916B1/en active Active
- 2017-07-07 BR BR112018004916A patent/BR112018004916A2/pt unknown
- 2017-07-07 CN CN201780036665.XA patent/CN109618556B/zh active Active
- 2017-07-07 UA UAA201812547A patent/UA124104C2/uk unknown
- 2017-07-07 AU AU2017295608A patent/AU2017295608B2/en active Active
- 2017-07-07 MX MX2019000476A patent/MX2019000476A/es unknown
- 2017-07-07 SM SM20210194T patent/SMT202100194T1/it unknown
- 2017-07-07 RS RS20210397A patent/RS61646B1/sr unknown
- 2017-07-07 PT PT177399409T patent/PT3484916T/pt unknown
- 2017-07-07 SI SI201730686T patent/SI3484916T1/sl unknown
- 2017-07-07 SG SG11201811015RA patent/SG11201811015RA/en unknown
- 2017-07-07 RU RU2018143423A patent/RU2760875C1/ru active
- 2017-07-07 PE PE2018003304A patent/PE20190227A1/es unknown
- 2017-07-07 CN CN202211523102.2A patent/CN116041504A/zh active Pending
- 2017-07-07 PL PL17739940T patent/PL3484916T3/pl unknown
- 2017-07-07 CA CA3027561A patent/CA3027561A1/en active Pending
- 2017-07-07 LT LTEP17739940.9T patent/LT3484916T/lt unknown
- 2017-07-07 PH PH1/2018/502613A patent/PH12018502613B1/en unknown
- 2017-07-07 WO PCT/EP2017/067067 patent/WO2018011073A1/en not_active Ceased
- 2017-07-07 MY MYPI2018002441A patent/MY197836A/en unknown
- 2017-07-10 US US15/645,442 patent/US10472415B2/en active Active
- 2017-07-10 TW TW106123060A patent/TWI747922B/zh active
-
2018
- 2018-12-05 IL IL263530A patent/IL263530B2/en unknown
- 2018-12-10 ZA ZA2018/08329A patent/ZA201808329B/en unknown
- 2018-12-12 DO DO2018000281A patent/DOP2018000281A/es unknown
- 2018-12-28 CO CONC2018/0014325A patent/CO2018014325A2/es unknown
-
2019
- 2019-01-07 SV SV2019005807A patent/SV2019005807A/es unknown
- 2019-01-10 CL CL2019000082A patent/CL2019000082A1/es unknown
- 2019-01-11 NI NI201900003A patent/NI201900003A/es unknown
- 2019-01-24 EC ECSENADI20195417A patent/ECSP19005417A/es unknown
- 2019-04-01 US US16/371,902 patent/US10647762B2/en active Active
- 2019-04-01 US US16/371,867 patent/US10487142B2/en active Active
- 2019-09-27 US US16/585,207 patent/US11111290B2/en active Active
-
2021
- 2021-03-26 CY CY20211100268T patent/CY1123995T1/el unknown
- 2021-08-11 US US17/399,205 patent/US12129289B2/en active Active
- 2021-10-05 JP JP2021164366A patent/JP7244600B2/ja active Active
-
2024
- 2024-03-05 AU AU2024201450A patent/AU2024201450A1/en active Pending
- 2024-09-24 US US18/895,231 patent/US20250257124A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12129289B2 (en) | Antibodies specific for hyperphosphorylated tau and methods of use thereof | |
| US11739140B2 (en) | Antibodies specific for hyperphosphorylated tau and methods of use thereof | |
| HK40059227A (en) | Antibodies specific for hyperphosphorylated tau and methods of use thereof | |
| HK40007700B (en) | Antibodies specific for hyperphosphorylated tau and methods of use thereof | |
| HK40007700A (en) | Antibodies specific for hyperphosphorylated tau and methods of use thereof | |
| EA039569B1 (ru) | Антитела, специфичные к гиперфосфорилированному тау-белку, и способы их применения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20190111 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20200706 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20220805 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20230330 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20230703 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20230703 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration |